readthroughSign in
Nov 5, 2026Financing4 fact check notes

Conexeu Sciences files two Form D notices for stock issued to consultants

The Nevada biotechnology company reported two small equity sales tied to consulting payments, dated October 28 and October 29, 2026.

Conexeu Sciences Inc., a Nevada corporation based in Reno, filed two Form D notices with the Securities and Exchange Commission, both signed by Chief Financial Officer Stephen Inouye on November 5, 2026.

The first notice listed a date of first sale of October 29, 2026. The filing reported one investor in the offering.1

The second notice listed a date of first sale of October 28, 2026. That filing reported two investors.2

Both notices claimed exemption under Rule 506(b) of Regulation D and stated no sales commissions or finders' fees were paid. Neither offering was made in connection with a business combination transaction such as a merger, acquisition or exchange offer.1 In both filings, the company reported its industry group as Biotechnology and declined to disclose revenue or net asset value ranges.

The filings listed the same set of related persons, including executive officers and directors David R. Bogart, Miles Harrison, Aaron Farberg, Stephen D. Inouye, Claudia Chavez-Munoz, Jeff Sharpe, Z Paul Lorenc, Sebastian Purcell, Brian Pilcher, Andrew Costa, April Burke and Ana Bastiani-Posner, all listed at the company's Reno address.

Fact check notes

  • ImpreciseRelated persons described as 'executive officers and directors'The blanket phrase 'executive officers and directors' slightly overstates that each listed person holds both roles, though collectively the group does include both.
  • Checker's noteThe entry describes the full list of twelve related persons collectively as 'executive officers and directors,' but individually most hold only one of the two roles (e.g., several are directors only, others are executive officers only).
  • Sentence removedThe total offering amount and total amount sold were each $4,801, representing 1,667 shares at a deemed price of $2.88 per share, issued as payment for consulting services.copied source wording
  • Sentence removedThe total offering amount and total amount sold were each $21,645, representing 6,500 shares at a deemed price of $3.33 per share, also issued as payment for consulting services.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.